Thyrotropin-releasing hormone and its analog MK-771 increase the cerebroventricular perfusate content of dihydroxyphenylacetic acid.
The effects of thyrotropin-releasing hormone (TRH) and its synthetic analog, pyro-2-aminoadipyl-histidyl-thiazolidine-4-carboxamide (MK-771), were determined on the efflux of dihydroxyphenylacetic acid (DOPAC) collected from push-pull cannulae chronically implanted into the lateral cerebral ventricles of rats. Intracerebroventricular and intraperitoneal injections of both peptides increased the efflux of DOPAC. These results suggest that TRH and MK-771 increase the activity of dopaminergic neurons that terminate in periventricular regions.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism*; D000818:Animals; D002552:Cerebral Ventricles / Q000187:drug effects / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D008297:Male; D010477:Perfusion; D010648:Phenylacetates / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D053778:Thiazolidines; D013973:Thyrotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology*
D010648:Phenylacetates; D053778:Thiazolidines; D015102:3,4-Dihydroxyphenylacetic Acid; D013973:Thyrotropin-Releasing Hormone; C021597:pyro(l-alpha-aminoadipyl)-L-histidyl-L-thiazolidine-4-carboxamide